Special Issue "Research, Advances, Challenges and Perspectives in the Development of Vaccines against Dengue, Zika and Chikungunya Viruses"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 31 December 2020.

Special Issue Editors

Dr. Wildriss Viranaicken
Website
Guest Editor
PIMIT, Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, Ile de La Réunion, France
Interests: Host-pathogen interaction, flavivirus, PAMPs, Innate immunity, antiviral response, live attenuated vaccines, antigen design and production, host-targeted antiviral
Dr. Pascale Krejbich
Website
Guest Editor
PIMIT, Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, Ile de La Réunion, France
Interests: Virus-Host interaction, arboviroses, programmed cell death, cell antiviral response, red queen effect

Special Issue Information

Dear Colleagues,

Zika (ZIKV), Dengue (DENV), and Chikungunya (CHIKV) viruses are arthropod-borne emerging or re-emerging pathogens mainly transmitted to humans by Aedes mosquitoes. With global warming and the spread of their mosquito vectors, these viruses are responsible for worldwide frequent outbreaks and constitute major public health problems. Beyond the classic clinical manifestations with fever, pain, rash, each virus is respectively responsible for serious complications such as haemorrhagic fever for DENV, congenital malformations for ZIKV, neurological complications like Guillain-Barré syndrome for CHIKV and ZIKV and chronic polyarthralgia for Chikungunya. The common feature of these viral infections is that there is no curative or prophylactic treatment. Vaccination, a prevention strategy, is the reference approach to a better public health and to limit future epidemics. To establish vaccines, it is necessary to define the host-pathogen interaction mechanisms and especially the molecular determinants of virulence. Among the challenges, it is necessary to consider the existence of the ADE phenomenon, a possible co-circulation of two or more of these viruses in endemic areas and the high prevalence of Guillain-Barré syndromes during some of these viral infections. A candidate vaccine must therefore be able to avoid inducing this type of response in humans and must be able to be used by the most vulnerable populations in endemic areas such as newborns or pregnant women. The purpose of this Special Issue “Research, advances, challenges and perspectives in the development of vaccines against Dengue, Zika and Chikungunya viruses” is to present the latest research results that advance our knowledge on the progress conception of vaccine strategies against these arboviruses. It is open to the submission of manuscripts, reviews, research, short communications, hypothesis, perspectives and point of view, that describe research or idea that can improve our knowledge on this issue for vaccines.

Dr. Wildriss Viranaicken
Dr. Pascale Krejbich
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Zika
  • dengue
  • chikungunya
  • congenital complication
  • Guillain-Barre syndrome
  • polyarthralgia
  • host-cell response
  • virulence factors
  • ADE
  • vaccine candidate
  • antigen

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle
A Simple and High-Throughput ELISA-Based Neutralization Assay for the Determination of Anti-Flavivirus Neutralizing Antibodies
Vaccines 2020, 8(2), 297; https://doi.org/10.3390/vaccines8020297 - 10 Jun 2020
Abstract
Mosquito-borne flavivirus infections, including dengue virus and Zika virus, are major public health threats globally. While the plaque reduction neutralization test (PRNT) is considered the gold standard for determining neutralizing antibody levels to flaviviruses, the assay is time-consuming and laborious. This study, therefore, [...] Read more.
Mosquito-borne flavivirus infections, including dengue virus and Zika virus, are major public health threats globally. While the plaque reduction neutralization test (PRNT) is considered the gold standard for determining neutralizing antibody levels to flaviviruses, the assay is time-consuming and laborious. This study, therefore, aimed to develop an enzyme-linked immunosorbent assay (ELISA)-based microneutralization test (EMNT) for the detection of neutralizing antibodies to mosquito-borne flaviviruses. The inhibition of viral growth due to neutralizing antibodies was determined colorimetrically by using EMNT. Given the significance of Fcγ-receptors (FcγR) in antibody-mediated neutralization and antibody-dependent enhancement (ADE) of flavivirus infection, non-FcγR and FcγR-expressing cell lines were used in the EMNT to allow the detection of the sum of neutralizing and immune-enhancing antibody activity as the neutralizing titer. Using anti-flavivirus monoclonal antibodies and clinical samples, the utility of EMNT was evaluated by comparing the end-point titers of the EMNT and the PRNT. The correlation between EMNT and PRNT titers was strong, indicating that EMNT was robust and reproducible. The new EMNT assay combines the biological functional assessment of virus neutralization activity and the technical advantages of ELISA and, is simple, reliable, practical, and could be automated for high-throughput implementation in flavivirus surveillance studies and vaccine trials. Full article
Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview
A Review on Dengue Vaccine Development
Vaccines 2020, 8(1), 63; https://doi.org/10.3390/vaccines8010063 - 02 Feb 2020
Cited by 1
Abstract
Dengue virus (DENV) has become a global health threat with about half of the world’s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second [...] Read more.
Dengue virus (DENV) has become a global health threat with about half of the world’s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D—tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in some countries, and many candidate vaccines are still under research and development. This review discusses the progress, strengths, and weaknesses of the five types of vaccines including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine. Full article
Back to TopTop